Buy 3-HO-PCP for sale online - USA vendor

Table of Contents

1. History and Culture
2. Chemistry
3. Pharmacology
4. Physical Effects
5. Disconnective Effects
6. Cognitive Effects
7. Auditory Effects
8. Visual Effects
9. Toxicity and Harm Potential
   • Lack of Scientific Study
   • Tolerance and Addiction Potential
   • Harm Reduction Practices
   • Urinary Tract Effects
   • Dangerous Interactions
   • Legal Status
10. FAQ

Exploring 3-HO-PCP: A Novel Dissociative Substance

Synthesis and Background

3-Hydroxyphencyclidine (commonly referred to as 3-HO-PCP) belongs to the arylcyclohexylamine class of substances, characterized by their dissociative, hallucinogenic, and euphoric effects upon administration. This compound acts primarily as a NMDA receptor antagonist, similar to its precursor phencyclidine (PCP), but notably, it also demonstrates affinity for the μ-opioid receptor.

First synthesized in 1978, 3-HO-PCP was developed to explore the structure-activity relationship of PCP derivatives. Subsequent research in the 1980s alongside PCP revealed its μ-opioid agonist activity in animal models.

Pharmacological Effects and Variability

3-HO-PCP, akin to other substances within its class such as methoxetamine (MXE), PCP, and 3-MeO-PCE, primarily induces a state known as "dissociative anesthesia." However, the degree of this effect varies significantly depending on dosage, leading to highly variable outcomes. It remains uncertain whether the observed opioid properties in animal models translate to humans, with early reports suggesting disparity.

Safety Concerns and Side Effects

Reports indicate that 3-HO-PCP may elicit notable physical side effects, including muscle soreness and flu-like symptoms either during or shortly after administration. This suggests potential increased danger or toxicity compared to related dissociatives, especially at higher doses.

Current Distribution and Recommendations

Presently, 3-HO-PCP is predominantly distributed as a research chemical within a legal gray area by online vendors. However, there exists a dearth of knowledge regarding its pharmacology, metabolism, and toxicity in humans. Given its sensitive dose-response relationship, potential for habit formation, and unknown toxicity profile, it is strongly advised to adhere to proper harm reduction practices for those considering its use.

History and Culture

Synthesis and Early Exploration

3-Hydroxyphencyclidine (3-HO-PCP) emerged onto the scientific scene in 1978, initially synthesized to explore the structure-activity relationship of phencyclidine (PCP) derivatives. Subsequent investigations alongside PCP during the 1980s revealed its μ-opioid agonist activity in animal models.

The compound's potential as a research chemical for human use was suggested in 1999 by a chemist known under the pseudonym John Q. Beagle. Beagle's report highlighted 3-HO-PCP's significantly increased potency compared to PCP, as well as its enhanced affinity for the opiate receptor, indicating potential analgesic activity.

In October 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom issued a report on methoxetamine, advocating for its classification as a Class B drug under the Misuse of Drugs Act (1971). This report proposed that all analogs of methoxetamine, including 3-HO-PCP, should also be classified as Class B drugs.

Chemistry

Structural Composition

3-HO-PCP, or 3-hydroxyphencyclidine, belongs to the arylcyclohexylamine class of synthetic dissociatives. Its chemical structure comprises a cyclohexane ring bonded to two additional rings at R1. One of these rings is a piperidine ring, while the other is an aromatic phenyl ring, substituted with a hydroxy group at R3.

This compound is a structural analog of PCP and a homolog of 3-MeO-PCP.

Pharmacology

Mechanism of Action

3-HO-PCP, like other arylcyclohexylamine dissociatives, primarily acts as an antagonist of the NMDA receptor. The NMDA receptor, a subtype of the glutamate receptor, regulates the transmission of electrical signals between neurons. Dissociatives disrupt normal NMDA receptor functioning by binding to and blocking these receptors, leading to disintegration of neural network activity. This disruption may cause cognitive and affective processing impairment, psychomotor dysfunction, and anesthesia.

Additionally, 3-HO-PCP has been found to exhibit significant affinity as a μ-opioid receptor agonist in animal models. However, its effects on humans in this regard remain uncertain.

Dosage Guidelines

Threshold to Heavy Dosage

• Threshold: 1 mg
• Light: 2 - 4 mg
• Common: 4 - 6 mg
• Strong: 6 - 8 mg
• Heavy: 8 mg and above

Redosing may lead to dangerous cumulative effects.

Physical Effects

Stimulation & Sedation

• Restless Legs
• Spontaneous Bodily Sensations
• Perception of Bodily Lightness
• Physical Euphoria: Notably induces euphoria more readily compared to other dissociatives like ketamine or diphenidine.
• Tactile Enhancement and Tactile Suppression: At lower dosages, induces tactile enhancements, while at higher dosages, shifts towards tactile suppression and anesthesia.
• Pain Relief: Can produce distinct nerve-signal blocking anesthetic effects, particularly in stronger to heavier dose ranges.
• Motor Control Loss
• Changes in Felt Gravity
• Spatial Disorientation: Prominent at high doses, unlike other dissociatives such as ketamine.
• Abnormal Heartbeat
• Increased Blood Pressure
• Increased Heart Rate
• Increased Perspiration
• Respiratory Depression
• Olfactory Hallucinations
• Optical Sliding
• Appetite Suppression
• Dehydration
• Dizziness
• Difficulty Urinating
• Orgasm Suppression
• Erectile Dysfunction
• Seizure: Extent of occurrence uncertain but likely in predisposed individuals, especially under physically taxing conditions like dehydration, fatigue, or malnutrition.

Disconnective Effects

Less Prominent Disconnective Effects

• Tactile Disconnection
• Visual Disconnection
• Consciousness Disconnection

Cognitive Effects

• Anxiety Suppression
• Disinhibition
• Cognitive Euphoria
• Compulsive Redosing: More pronounced based on the route of administration; particularly present when smoked or vaporized.
• Conceptual Thinking
• Immersion Enhancement
• Creativity Enhancement
• Déjà Vu
• Depersonalization & Derealization
• Delusion
• Memory Suppression
• Ego Death
• Amnesia
• Increased Music Appreciation
• Time Distortion
• Thought Connectivity
• Thought Deceleration
• Thought Disorganization
• Psychosis

Auditory Effects

• Suppression
• Distortions
• Hallucinations

Visual Effects

• Visual Acuity Suppression
• Double Vision
• Frame Rate Suppression
• Pattern Recognition Suppression
• Distortions
• Perspective Distortions
• Scenery Slicing
• Hallucinatory States
• Internal Hallucination: Settings, sceneries, landscapes; perspective hallucinations, scenarios, and plots.

Toxicity and Harm Potential

Lack of Scientific Study

The toxicity and long-term health effects of recreational 3-HO-PCP use remain largely unstudied in scientific contexts, with the exact toxic dosage unknown due to the compound's brief history of human usage.

Tolerance and Addiction Potential

• Moderate Addiction Potential: Early reports suggest chronic use of 3-HO-PCP may lead to moderate addiction with potential adverse effects such as psychosis.
• Habit-Forming Nature: Similar to 3-MeO-PCP, 3-HO-PCP may be more habit-forming than other dissociatives like MXE, diphenidine, ephenidine, DCK, and ketamine.
• Tolerance Development: Prolonged and repeated use may result in tolerance, necessitating larger doses for desired effects. Cross-tolerance with other dissociatives likely occurs.
• Withdrawal Effects: Cravings and withdrawal effects may occur upon cessation of usage.

Harm Reduction Practices

• Caution and Moderation: Exercise extreme caution and moderation when using 3-HO-PCP.
• Avoid Dependency: Refrain from consecutive daily usage to prevent dependence and associated adverse effects.
• Dosage Control: Adhere to recommended dosage ranges to avoid triggering harmful effects.
• Volumetric Dosing: Use volumetric dosing for precise administration due to the drug's potency.
• Avoid Compulsive Redosing: Refrain from compulsive redosing before fully sober to prevent unpredictable side effects.
• Avoid Combination with Other Substances: Due to the risk of psychosis, avoid combining 3-HO-PCP with stimulants, psychedelics, or other dissociatives without thorough research on safety.

Urinary Tract Effects

Ketamine-like Symptoms

3-HO-PCP may induce similar bladder and urinary tract issues as ketamine, albeit to a lesser extent due to its higher potency. Symptoms may include:

• Urinary Frequency
• Urinary Urgency
• Urinary Pressure
• Pelvic and Bladder Pain
• Hematuria
• Incontinence

Dangerous Interactions

Stimulants and Depressants

• Stimulants: Combining with stimulants can heighten risks of adverse psychological reactions and exacerbate psychosis.
• Depressants: Concurrent use with depressants may increase the risk of respiratory depression, unconsciousness, vomiting, and suffocation.

Legal Status

Varied Legal Status

• Germany: Not a controlled substance but illegal for human consumption.
• Switzerland: Controlled substance under Verzeichnis E.
• Turkey: Classified as illegal to possess, produce, supply, or import.
• United Kingdom: Class B drug under the Misuse of Drugs Act, illegal to possess, produce, supply, or import. Covered by the arylcyclohexylamine generic clause.

FAQ (Frequently Asked Questions)

Q: What is 3-HO-PCP?

A: 3-Hydroxyphencyclidine (3-HO-PCP) is a novel dissociative substance belonging to the arylcyclohexylamine class known for its potent dissociative, hallucinogenic, and euphoric effects.

Q: How was 3-HO-PCP discovered?

A: It was first synthesized in 1978 to study the structure-activity relationship of phencyclidine (PCP) derivatives and further explored in the 1980s, revealing its μ-opioid agonist activity in animal models.

Q: What are the primary effects of 3-HO-PCP?

A: The primary effects include dissociation, hallucinations, euphoria, and analgesia. However, the extent of these effects can vary depending on dosage and individual tolerance.

Q: Is 3-HO-PCP addictive?

A: Early reports suggest that chronic use of 3-HO-PCP may lead to moderate addiction with potential adverse effects such as psychosis.

Q: How can I reduce harm while using 3-HO-PCP?

A: Harm reduction practices include using caution and moderation, avoiding consecutive daily usage, adhering to recommended dosage ranges, and avoiding combination with other substances, especially stimulants and depressants.

Q: What are the legal implications of using 3-HO-PCP?

A: Legal status varies by country. In the United Kingdom, for example, it is classified as a Class B drug and is illegal to possess, produce, supply, or import.

Q: What are the potential urinary tract effects of 3-HO-PCP?

A: Similar to ketamine, 3-HO-PCP may induce urinary frequency, urgency, pressure, pain, hematuria, and incontinence with prolonged and excessive use.

Q: Are there dangerous interactions associated with 3-HO-PCP?

A: Yes, combining 3-HO-PCP with stimulants or depressants can increase the risk of adverse psychological reactions, respiratory depression, unconsciousness, vomiting, and suffocation.